These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 200243)

  • 41. Factors affecting prostaglandin endoperoxide transformation: antibodies against PGH2.
    Fitzpatrick FA; Pike JE
    Prog Lipid Res; 1981; 20():179-82. PubMed ID: 7342082
    [No Abstract]   [Full Text] [Related]  

  • 42. Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets.
    Best LC; Martin TJ; Russell RG; Preston FE
    Nature; 1977 Jun; 267(5614):850-2. PubMed ID: 197414
    [No Abstract]   [Full Text] [Related]  

  • 43. Mechanism of the inhibition of platelet aggregation produced by prostaglandin F2 alpha.
    Armstrong RA; Jones RL; Wilson NH
    Prostaglandins; 1985 Apr; 29(4):601-10. PubMed ID: 2988022
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A structural requirement for the conversion of prostaglandin endoperoxides to thromboxanes.
    Diczfalusy U; Hammarström S
    FEBS Lett; 1979 Sep; 105(2):291-5. PubMed ID: 488357
    [No Abstract]   [Full Text] [Related]  

  • 45. Platelet membranes, eicosanoid biosynthesis and putative endogenous calcium ionophores.
    Carey F; Menashi S; Authi KS; Hack N; Lagarde M; Crawford N
    Adv Exp Med Biol; 1985; 192():185-99. PubMed ID: 2422885
    [No Abstract]   [Full Text] [Related]  

  • 46. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
    Parry MJ
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2.
    Gresele P; Deckmyn H; Huybrechts E; Vermylen J
    Biochem Pharmacol; 1984 Jul; 33(13):2083-8. PubMed ID: 6430299
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour.
    Sills T; Heptinstall S
    Thromb Haemost; 1986 Jun; 55(3):305-8. PubMed ID: 3018954
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Familial bleeding tendency with partial platelet thromboxane synthetase deficiency: reorientation of cyclic endoperoxide metabolism.
    Defreyn G; Machin SJ; Carreras LO; Dauden MV; Chamone DA; Vermylen J
    Br J Haematol; 1981 Sep; 49(1):29-41. PubMed ID: 6268139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential effects of cyclo-oxygenase inhibitors and thromboxane synthase inhibitors on rabbit platelet aggregation: evidence for the importance of prostaglandin endoperoxides as mediators in arachidonate-induced aggregation but not in collagen-induced aggregation.
    Wallis RB; Zelaschi D
    Biochem Soc Trans; 1980 Dec; 8(6):726-7. PubMed ID: 6780392
    [No Abstract]   [Full Text] [Related]  

  • 51. Pulmonary vascular responses to thromboxane A2 as unmasked by OKY-1581. A novel inhibitor of thromboxane synthesis.
    Kadowitz PJ; Nandiwada PA; Spannhake EW; Rosenson RS; McNamara DB; Hyman AL
    Chest; 1983 May; 83(5 Suppl):72S-74S. PubMed ID: 6404609
    [No Abstract]   [Full Text] [Related]  

  • 52. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
    Hoet B; Arnout J; Deckmyn H; Vermylen J
    Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acetyl glycerylphosphorylcholine inhibition of prostaglandin I2-stimulated adenosine 3',5'-cyclic monophosphate levels in human platelets. Evidence for thromboxane A2 dependence.
    Miller OV; Ayer DE; Gorman RR
    Biochim Biophys Acta; 1982 Jun; 711(3):445-51. PubMed ID: 6285985
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of platelet thromboxane synthetase by L-1-tosylamido-2-phenylethyl chloromethyl ketone.
    Yahn DM; Feinstein MB
    Prostaglandins; 1981 Feb; 21(2):243-54. PubMed ID: 7194491
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effects of amrinone on human platelet aggregation: evidence that amrinone does not act through a cyclic nucleotide mechanism in platelet rich plasma.
    Lippton HL; Horwitz PM; McNamara DB; Ignarro LJ; Landry AZ; Hyman AL; Kadowitz PJ
    Prostaglandins Leukot Med; 1985 May; 18(2):193-204. PubMed ID: 3925461
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contractile responses of intrapulmonary vessels from three species to arachidonic acid and an epoxymethano analog of PGH2.
    Gruetter CA; McNamara DB; Hyman AL; Kadowitz PJ
    Can J Physiol Pharmacol; 1978 Apr; 56(2):206-15. PubMed ID: 638873
    [No Abstract]   [Full Text] [Related]  

  • 57. The affinities of prostaglandin H2 and thromboxane A2 for their receptor are similar in washed human platelets.
    Mayeux PR; Morton HE; Gillard J; Lord A; Morinelli TA; Boehm A; Mais DE; Halushka PV
    Biochem Biophys Res Commun; 1988 Dec; 157(2):733-9. PubMed ID: 2974286
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thromboxane synthetase inhibition.
    Tyler HM
    Lancet; 1981 Jun; 1(8233):1313-4. PubMed ID: 6112625
    [No Abstract]   [Full Text] [Related]  

  • 59. Inhibition of PGE1-stimulated cAMP accumulation in human platelets by thromboxane a2.
    Miller OV; Johnson RA; Gorman RR
    Prostaglandins; 1977 Apr; 13(4):599-609. PubMed ID: 193153
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.
    Fitzgerald DJ; Fragetta J; FitzGerald GA
    J Clin Invest; 1988 Nov; 82(5):1708-13. PubMed ID: 3183064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.